Reversal of scopolamine-induced spatial memory deficits in rats by TAK-147.
Abstract
AIM: To evaluate effect of TAK-147 on spatial memory deficit induced by
scopolamine.
METHODS: Morris water maze was used to measure spatial memory in rats and open
field test was used to analyse locomotor activity.
RESULTS: In the acquisition memory process, scopolamine (0.4 mg/kg, ip) markedly
increased the escape latency to the platform. Ip injection of both TAK-147 and
donepezil ameliorated scopolamine-induced deficit, dose-related and significant
effect was obtained at doses of 0.1-1.0 mg/kg. In the memory retrieval process,
increased latency induced by scopolamine (1.5 mg/kg, ip) was also significantly
reversed by treatment with TAK-147 (0.1, 0.3, and 1.0 mg/kg), donepezil (0.3 and
1.0 mg/kg), and tacrine (3 and 5 mg/kg), respectively. TAK-147 has a little
potent efficacy to donepezil, and was more potent than tacrine. In the locomotor
test, both TAK-147 and donepizil created no appreciable change of locomotor
activities, compared with scopolamine or saline.
CONCLUSION: TAK-147 plays an important role in spatial cognition, and this result
provides additional evidence that TAK-147 is an ideal AChE inhibitor and is
useful for the treatment of Alzheimer's disease.
Keywords:
scopolamine.
METHODS: Morris water maze was used to measure spatial memory in rats and open
field test was used to analyse locomotor activity.
RESULTS: In the acquisition memory process, scopolamine (0.4 mg/kg, ip) markedly
increased the escape latency to the platform. Ip injection of both TAK-147 and
donepezil ameliorated scopolamine-induced deficit, dose-related and significant
effect was obtained at doses of 0.1-1.0 mg/kg. In the memory retrieval process,
increased latency induced by scopolamine (1.5 mg/kg, ip) was also significantly
reversed by treatment with TAK-147 (0.1, 0.3, and 1.0 mg/kg), donepezil (0.3 and
1.0 mg/kg), and tacrine (3 and 5 mg/kg), respectively. TAK-147 has a little
potent efficacy to donepezil, and was more potent than tacrine. In the locomotor
test, both TAK-147 and donepizil created no appreciable change of locomotor
activities, compared with scopolamine or saline.
CONCLUSION: TAK-147 plays an important role in spatial cognition, and this result
provides additional evidence that TAK-147 is an ideal AChE inhibitor and is
useful for the treatment of Alzheimer's disease.